O
TRML

OrbiMed’s Tourmaline Bio TRML Stock Holding History

OrbiMed’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-23,600
Closed -$1.06K – 148
2022
Q2 		$1.06K Sell
23,600
-1,124
-5% -$88.7K 0.02% 139
2022
Q1 		$2.43M Hold
24,724
– – 0.04% 129
2021
Q4 		$3.78M Hold
24,724
– – 0.05% 140
2021
Q3 		$3.35M Hold
24,724
– – 0.04% 162
2021
Q2 		$3.63M Buy
+24,724
New +$3.79M 0.04% 152

Other funds holding TRML

Blackstone Inc
Blackstone Inc New York $24.2B AUM 26.83% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.98B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return